🧬 BioDrug Intelligence

An Evidence-Driven Pharmacogenomics Research Platform

Connecting Genetic Variation, Medication Response Research, and Biomedical Evidence

---

1. Project Overview

BioDrug Intelligence is a Python-based pharmacogenomics research platform designed to organize genetic information, explore gene–drug relationships, and support evidence-oriented biomedical investigation.

The project brings together software engineering, genetic data processing, biomedical evidence management, graphical interfaces, and structured reporting.

Its central objective is to provide a modular foundation for investigating how genetic variation may influence medication response.

The platform is intended to make research workflows more structured, transparent, and reproducible.

Project Mission

To build an extensible computational environment that helps users organize genetic findings and examine relevant pharmacogenomic evidence.

Project Vision

To support the development of more accessible, traceable, and evidence-informed pharmacogenomics research tools.

Core Principles

• Scientific transparency.
• Traceable evidence.
• Reproducible software behavior.
• Responsible handling of genetic data.
• Modular architecture.
• Clear documentation.
• Explicit uncertainty.
• Continuous evaluation.
• Maintainable code.
• Responsible innovation.

---

2. The Scientific Problem

Individuals can respond differently to the same medication. Genetic variation is one factor that may contribute to differences in drug metabolism, drug transport, treatment response, and adverse-reaction risk.

Pharmacogenomics investigates these relationships.

However, genetic findings, medication information, research studies, and clinical guidelines are often distributed across different resources.

BioDrug Intelligence aims to provide a software foundation for organizing these information sources into a coherent research workflow.

The project does not assume that every genetic variant has a known effect or that every gene–drug relationship supports a clinical recommendation.

Its analytical outputs must be interpreted in the context of the available evidence.

---

3. Intended Use

BioDrug Intelligence is designed for:

• Pharmacogenomics research and experimentation.
• Software development involving genetic information.
• Educational demonstrations of biomedical data workflows.
• Exploration of gene–drug evidence.
• Structured organization of genetic profiles.
• Development of evidence retrieval systems.
• Reproducible computational experiments.
• Research-oriented reporting.
• Evaluation of biomedical software components.
• Future development of validated analytical methods.

The project is not a substitute for professional medical care or official prescribing guidance.

---

4. Core Research Workflow

GENETIC INFORMATION
        |
        v
PROFILE VALIDATION
        |
        v
VARIANT ORGANIZATION
        |
        v
GENE AND DRUG IDENTIFICATION
        |
        v
BIOMEDICAL EVIDENCE RETRIEVAL
        |
        v
EVIDENCE REVIEW
        |
        v
STRUCTURED RESEARCH OUTPUT
        |
        v
REPORTING AND EVALUATION

Each stage should have defined inputs, outputs, validation rules, and tests.

A successful data import does not automatically establish the biological significance of an imported variant.

Likewise, finding a gene–drug association does not automatically establish that a medication is appropriate for a particular individual.

---

5. Genetic Profile Management

Genetic profiles provide a structured representation of selected genetic findings.

A profile may contain:

• A profile identifier.
• A non-identifying display label.
• Variant identifiers.
• Gene symbols.
• Genotype information where available.
• Reference genome information where applicable.
• Source metadata.
• Import timestamps.
• Data quality indicators.
• Validation warnings.

The implementation should distinguish missing information from confirmed reference alleles.

Profiles should remain editable and should preserve the meaning of their original source records.

Where local persistence is implemented, saved profiles should remain available after restarting the application.

Profile import and export workflows should validate the expected format and protect sensitive information.

---

6. Genetic Variant Processing

Variant processing is an important component of pharmacogenomics research.

A robust workflow may include:

1. Input format validation.
2. Variant identifier parsing.
3. Gene symbol resolution.
4. Chromosome and position validation.
5. Reference genome identification.
6. Reference and alternate allele validation.
7. Variant normalization where supported.
8. Duplicate detection.
9. Source identifier preservation.
10. Error reporting.
11. Data quality checks.
12. Evidence linkage.

Genomic coordinates must be interpreted in the context of the relevant reference genome build.

Variants that appear different in text may represent equivalent genomic changes. Normalization and consistent reference information can therefore be important when comparing records.

Uncertain or incomplete inputs should not be silently converted into definitive genetic findings.

---

7. Gene–Drug Research

The gene–drug research component is intended to connect relevant genetic information with available medication-related evidence.

Potential analytical steps include:

• Identifying relevant gene records.
• Resolving medication names.
• Searching for known gene–drug relationships.
• Retrieving associated evidence.
• Preserving source metadata.
• Identifying conflicting findings.
• Presenting relevant uncertainty.
• Organizing results for review.
• Generating structured research summaries.
• Recording analysis configuration.

Medication names may have synonyms, brand names, formulations, and related compounds. Matching must account for ambiguity rather than treating every similar name as equivalent.

The presence of a genetic association alone does not establish a treatment recommendation.

---

8. Biomedical Evidence Management

Evidence management is central to the project's research goals.

Where supported by the implementation, an evidence record should preserve:

• Source name.
• Source identifier.
• Source URL.
• Record title.
• Publication date.
• Retrieval date.
• Evidence category.
• Relevant gene.
• Relevant medication.
• Source-specific interpretation.
• Limitations.
• Version information.

Evidence provenance makes it possible to understand where a result originated and which source supports it.

Conflicting evidence should remain visible rather than being silently merged into a single conclusion.

An evidence summary should not be presented as a direct quotation or official recommendation unless it accurately represents the original source.

---

9. Scientific Data Resources

The following resources are relevant to the project's domain. Their inclusion in this documentation does not imply that every resource is already integrated into the current release.

ClinVar

Website: https://www.ncbi.nlm.nih.gov/clinvar/

ClinVar provides information about reported relationships between genetic variants and human health conditions.

Potential applications include variant record retrieval, source identifier tracking, and structured data import.

Records may be updated, and submissions can contain conflicting interpretations.

CPIC

Website: https://cpicpgx.org/

The Clinical Pharmacogenetics Implementation Consortium publishes pharmacogenetics guidelines.

These guidelines may support research into gene–drug relationships when the relevant recommendations and supporting information are available.

PharmGKB

Website: https://www.pharmgkb.org/

PharmGKB provides curated pharmacogenomic knowledge and information about relationships between genetic variation and medication response.

Source terms, availability, and redistribution conditions should be reviewed before integration.

NCBI

Website: https://www.ncbi.nlm.nih.gov/

NCBI provides biomedical and genetic information resources that may support future data integrations.

FDA

Website: https://www.fda.gov/

The United States Food and Drug Administration provides official drug information and relevant pharmacogenomic labeling resources.

Any integration should preserve source context and avoid converting general labeling information into unsupported personalized advice.

---

10. Evidence Retrieval

Evidence retrieval should be designed to produce traceable results.

A retrieval workflow may include:

• Input validation.
• Identifier normalization.
• Exact matching.
• Controlled synonym matching.
• Source filtering.
• Duplicate handling.
• Relevance ordering.
• Evidence grouping.
• Source linking.
• No-result reporting.
• Conflict reporting.
• Retrieval diagnostics.

Exact matches and approximate matches should be distinguishable.

An empty search result does not prove that no relevant evidence exists anywhere.

Search results should identify the sources actually consulted and indicate relevant limitations.

---

11. Analysis and Interpretation

The analysis layer should separate data processing from interpretation.

A structured analysis may contain:

• Input profile information.
• Relevant variant records.
• Relevant gene–drug relationships.
• Retrieved evidence.
• Source references.
• Data quality warnings.
• Unresolved questions.
• Analytical limitations.
• Software version.
• Analysis timestamp.

Where an interpretation method is implemented, its assumptions should be documented.

Where no supported interpretation is available, the software should report insufficient evidence rather than invent a result.

An exploratory research result should not be described as a clinical diagnosis.

---

12. Accuracy and Validation

BioDrug Intelligence is intended to support measurable improvement in analytical reliability.

A target such as 98% accuracy must be associated with a precisely defined task and a reproducible evaluation method.

A defensible evaluation should specify:

• The task being measured.
• The evaluation dataset.
• The reference answers.
• The number of test cases.
• The criteria for a correct result.
• The handling of missing answers.
• The separation of development and test data.
• The evaluation metrics.
• The major error categories.
• The limitations of the benchmark.

Accuracy is not appropriate for every task. Depending on the analytical problem, precision, recall, sensitivity, specificity, calibration, and coverage may be more informative.

A high score on one dataset does not automatically establish safety across medications, populations, or clinical settings.

Suggested Evaluation Procedure

1. Define the analytical task.
2. Obtain an appropriate reference dataset.
3. Document inclusion and exclusion criteria.
4. Separate development data from held-out test data.
5. Run the system using a fixed configuration.
6. Compare outputs against reference answers.
7. Count correct, incorrect, missing, and uncertain results.
8. Calculate the appropriate metrics.
9. Investigate important failure modes.
10. Publish the method and results.

The project should report an achieved accuracy percentage only when supported by actual evaluation results.

---

13. Graphical User Interface

The graphical interface is intended to make the research workflow accessible without requiring every operation to be performed manually in a terminal.

Interface quality should be assessed through practical usability and responsiveness.

Relevant design principles include:

• Clear visual hierarchy.
• Consistent spacing.
• Readable typography.
• Predictable navigation.
• Responsive controls.
• Meaningful progress indicators.
• Helpful error messages.
• Accessible interaction.
• Clear empty states.
• Safe handling of sensitive information.

Long-running imports and searches should not unnecessarily block the interface.

Visual animation should not interfere with important information or make the application difficult to use.

The interface should communicate whether a process is running, completed, failed, or awaiting user input.

---

14. Command-Line Interface

The command-line interface provides an alternative way to interact with supported application functions.

The intended console command is:

biodrug

The command is available only when the package's entry point has been configured correctly and the package has been installed in the active Python environment.

A console entry point should:

• Invoke a real implementation.
• Provide clear error messages.
• Work independently of the current working directory where intended.
• Resolve packaged resources reliably.
• Return meaningful exit codes.
• Avoid requiring undocumented files outside the package.
• Have an installation test.

Graphical and command-line launch behavior should be documented separately if they use different entry points.

---

15. Database and Persistence

A local database can support structured storage of genetic profiles, variants, evidence records, and analysis metadata.

Where SQLite is used, important engineering considerations include:

• Schema consistency.
• Transaction handling.
• Appropriate indexes.
• Duplicate prevention.
• Database integrity.
• Import recovery.
• Backup and restoration.
• Migration between schema versions.
• Connection management.
• Error reporting.

Data imports should report the number of records processed and the number of records rejected or skipped.

Large imports should be tested with representative datasets rather than assuming that successful operation on a small sample guarantees reliable behavior at scale.

---

16. Data Import and Integrity

Every external dataset should have a documented origin and a defined import process.

A robust import procedure should:

1. Identify the source and release.
2. Validate the input file.
3. Confirm the expected fields.
4. Check the encoding.
5. Validate records.
6. Detect duplicates.
7. Record import progress.
8. Handle errors.
9. Commit data safely.
10. Verify final record counts.

Imported information should not be treated as authoritative merely because it was accepted by a parser.

Source licensing and redistribution requirements should be reviewed before bundling external data with the package.

---

17. Privacy and Security

Genetic information can be highly sensitive.

Responsible handling should include:

• Minimizing unnecessary data collection.
• Protecting local files.
• Avoiding hard-coded credentials.
• Removing secrets from logs.
• Documenting network requests.
• Validating imported file paths.
• Limiting access to exported reports.
• Providing clear data deletion procedures.
• Reviewing applicable privacy requirements.

If remote services are introduced, users should be informed about what data is transmitted and why.

The default research workflow should not silently upload personal genetic information.

---

18. Testing Strategy

Testing helps establish whether implemented software behavior matches expectations.

Potential test categories include:

Unit Tests

Test small, isolated functions such as parsers, validators, and transformation routines.

Integration Tests

Test interactions between the database, evidence retrieval, and analysis modules.

Packaging Tests

Verify that modules and resources are included in the built distribution.

Command Tests

Verify that documented console commands invoke the expected application behavior.

Data Import Tests

Use valid, invalid, incomplete, and duplicate records to evaluate import behavior.

Regression Tests

Protect previously corrected behavior against accidental changes.

User Interface Tests

Check important interface workflows where practical.

A passing software test suite does not establish clinical accuracy unless the tests explicitly evaluate the relevant scientific claims against appropriate reference data.

---

19. Installation

Requirements

• Python version supported by the package metadata.
• The project's declared runtime dependencies.
• Optional interface dependencies where applicable.
• Access to the required data files.

Create a Virtual Environment

python -m venv .venv

Windows

.venv\Scripts\activate
python -m pip install --upgrade pip
python -m pip install -e .

macOS and Linux

source .venv/bin/activate
python3 -m pip install --upgrade pip
python3 -m pip install -e .

The editable installation is intended for development from the project directory.

If the project declares additional dependencies for the graphical interface or other optional features, install them according to the package configuration.

---

20. Running the Application

If the project provides run_gui.py, run the graphical interface from the project root:

python run_gui.py

If the biodrug console entry point is correctly configured and installed:

biodrug

If a command cannot be found, verify that the correct virtual environment is active and that the package has been installed into that environment.

If the interface fails to open, inspect the full traceback and verify that the required interface dependencies are installed.

---

21. Running Tests

If the project uses Python's built-in unittest framework:

python -m unittest discover -s tests -v

If pytest is installed and configured:

python -m pytest -v

Record the Python version, operating system, dependency versions, and test results when preparing a release.

Tests should be repeatable and should not depend on private personal data.

---

22. Package Structure

The following is an illustrative structure. Actual files should match the repository.

BioDrug-Intelligence/
├── README.md
├── pyproject.toml
├── run_gui.py
├── biodrug/
│   ├── __init__.py
│   ├── cli.py
│   ├── launcher.py
│   ├── profile.py
│   ├── models.py
│   ├── evidence.py
│   ├── analysis.py
│   └── reports.py
├── tests/
│   ├── test_imports.py
│   ├── test_profiles.py
│   └── test_evidence.py
├── data/
├── docs/
└── LICENSE

The listed module names are examples, not a guarantee that every file exists in a particular release.

The actual package layout should be verified before documenting individual modules as implemented.

---

23. Package Metadata

The project uses pyproject.toml to describe packaging configuration.

Important metadata includes:

• Distribution name.
• Version.
• Short description.
• README location.
• Supported Python versions.
• Runtime dependencies.
• Optional development dependencies.
• Console entry points.
• Package discovery rules.

The distribution name used by pip can differ from the import package name used by Python code.

All metadata should be consistent with the actual source tree and supported installation workflow.

---

24. Building a Distribution

Install the build tools:

python -m pip install --upgrade build twine

Build the package:

python -m build

Check the generated distribution metadata:

python -m twine check dist/*

Before publishing, install the generated artifact in a clean environment and test the documented launch command.

Successful packaging checks establish that the distribution passes those checks. They do not independently establish the scientific validity of the software.

---

25. Publishing to PyPI

Before publishing a release:

1. Verify that the package name is correct.
2. Confirm that the version has not already been published.
3. Check that the README renders properly.
4. Confirm that the distribution contains the intended modules.
5. Remove secrets and private data.
6. Review third-party licenses.
7. Run the available tests.
8. Verify installation from the built distribution.
9. Prepare release notes.
10. Publish using a securely stored PyPI token.

A new release should use an appropriate new version number.

Never place an API token or password in the README, source code, or public repository.

---

26. Error Handling

Errors should be informative, specific, and safe.

Examples of useful error categories include:

• Invalid input format.
• Missing required field.
• Unsupported variant representation.
• Unknown gene identifier.
• Ambiguous medication name.
• Evidence source unavailable.
• Database write failure.
• Incomplete import.
• Missing optional dependency.
• Unsupported configuration.

Error messages should help users identify the next step without exposing secrets or unnecessary personal data.

Where appropriate, errors should include a stable error code for logging and automated tests.

---

27. Reproducibility

Reproducible research requires more than retaining the final output.

Where practical, record:

• Software version.
• Dataset release.
• Source retrieval date.
• Analysis configuration.
• Relevant input identifiers.
• Method version.
• Evaluation dataset version.
• Test environment.
• Known limitations.

Avoid recording raw sensitive genetic information in public logs or issue reports.

A reproducible result should be traceable to its inputs, methods, and source evidence.

---

28. Responsible Interpretation

Genetic associations vary in evidence strength and clinical relevance.

An appropriate research workflow should distinguish:

• Directly observed input data.
• Retrieved source information.
• Computed intermediate values.
• Software-generated summaries.
• Uncertain findings.
• Unsupported questions.
• Clinically reviewed recommendations.

The software should not manufacture a confident interpretation when important information is absent.

Users should consult qualified healthcare professionals before making medication decisions.

---

29. Development Roadmap

Potential future improvements include:

• Expanded source integrations.
• Improved variant normalization.
• Stronger identifier resolution.
• Richer evidence provenance.
• Additional reproducible benchmarks.
• Better error recovery.
• Improved interface accessibility.
• More comprehensive automated tests.
• Enhanced report generation.
• Database migration support.
• More complete package documentation.
• Performance testing on representative datasets.
• Improved privacy controls.
• Better source update monitoring.
• Independent scientific evaluation.

Roadmap items should be marked complete only when their implementation and tests have been reviewed.

---

30. Demonstration Guide

For a scientific or educational presentation:

1. Introduce the problem of variation in medication response.
2. Explain the purpose of pharmacogenomics.
3. Show the application interface.
4. Load a prepared synthetic example.
5. Demonstrate a supported profile workflow.
6. Retrieve a relevant evidence record.
7. Open the original source.
8. Explain what the result means and does not mean.
9. Demonstrate how missing evidence is handled.
10. Run the automated tests.
11. Describe the evaluation methodology.
12. Present limitations and future research directions.

Do not expose real personal genetic information during a public demonstration without appropriate authorization and safeguards.

---

31. Contribution Guidelines

Contributions should improve reliability, maintainability, documentation, or scientific traceability.

Before submitting a change:

• Describe the intended behavior.
• Include a reproducible test case.
• Avoid uploading sensitive genetic data.
• Keep the change focused.
• Document new configuration.
• Update affected tests.
• Check source licensing.
• Explain changes to data schemas.
• Update relevant documentation.
• Report known limitations.

Scientific corrections should include authoritative references whenever possible.

---

32. License

The applicable license must be specified in the repository's LICENSE file and package metadata.

Before redistribution, verify the terms governing third-party software, datasets, documentation, and other bundled materials.

Do not assume that publicly accessible biomedical data can automatically be redistributed without conditions.

---

33. Acknowledgments

BioDrug Intelligence builds on the broader scientific and software ecosystem supporting genetics, pharmacogenomics, biomedical research, and open-source development.

Relevant resources include ClinVar, CPIC, PharmGKB, NCBI, and FDA publications, subject to the sources actually used by a given release.

Each integrated source should be credited according to its applicable terms.

---

34. Final Statement

BioDrug Intelligence is a research-oriented software project exploring how genetic information and medication-related evidence can be organized into a structured computational workflow.

Its long-term value depends on reliable engineering, traceable scientific sources, reproducible evaluation, responsible data handling, and transparent communication of uncertainty.

BioDrug Intelligence — Turning pharmacogenomic information into structured, evidence-oriented research.

Research responsibly. Validate carefully. Keep the evidence traceable.